title: Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions.
abstract: Mouse monoclonal antibody, ONS-M21, directed against human medulloblastoma cells, has been humanized by complementarity determining region (CDR) grafting. A humanized ONS-M21 VH region, comparable to the original mouse ONS-M21 VH region, was easily constructed based on framework regions (FRs) 1, 2 and 3 from human EU antibody and on FR4 from human ND antibody. Five alterations in the FRs were made at amino acids 27, 28, 29, 30 and 94 which are all part of the canonical structure for CDR1 (H1). The humanized ONS-M21 VL regions were constructed based on the FRs from human REI antibody. We first identified five amino acid residues in the FRs at positions 20, 21, 71, 73 and 87 as having a possible adverse influences on antigen binding. None of the versions with a variety of combinations at these five positions showed any bindings to antigen. In order to identify the mouse residues that must be retained in the human FRs, hybrid VL regions were constructed by joining the mouse ONS-M21 VL region and the first humanized version within CDR2. The hybrid VL regions revealed that residues in FR1 and/or FR2 were critical in creating a functional antigen binding site. Redesigning several versions with alterations in FR1 and FR2 revealed that the Pro-46 residue was the only critical residue for creating an antigen binding site. This approach should be helpful in identifying key residues in difficult cases of antibody humanization.
authors.affiliation: Chugai Pharmaceutical Co. Ltd, Fuji-Gotemba Research Laboratories, Shizuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ohtomo
authors.forename: M
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: S
authors.initials: S
authors.lastname: Moriuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Miyao
authors.forename: T
authors.initials: T
authors.lastname: Akimoto
authors.forename: K
authors.initials: K
authors.lastname: Akamatsu
authors.forename: T
authors.initials: T
authors.lastname: Hayakawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohsugi
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000737:chemistry*; D000937:Antigen-Antibody Reactions; D005803:Genes, Immunoglobulin; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics; D008527:Medulloblastoma / Q000276:immunology*; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D016415:Sequence Alignment; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins